Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer

NCT02083679 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

15

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor the return rights of the compound to the collaboration partner for further clinical development

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine
DRUG: Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed
DRUG: Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel
DRUG: Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel

Sponsor

EMD Serono